The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising such antagonists.
